[RELATE] A Phase II Study of Retifanlimab (anti-PD-1), INCAGN02385 (anti-LAG-3), and INCAGN02390 (anti-TIM-3) as Second Line Treatment for Locally Advanced or Metastatic Squamous Cell Anal Cancer